6CM
MAIA icon

683 Capital Management’s MAIA Biotechnology MAIA Stock Holding History

683 Capital Management’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.49M Buy
+1,066,666
New +$1.97M 0.08% 126

Other funds holding MAIA

SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

683 Capital Management's MAIA Position: Q1 2026 in Review

683 Capital Management opened a new position in MAIA Biotechnology (MAIA) in Q1 2026: 1,066,666 shares worth $1.49M. The stake represents 0.08% of the portfolio and ranks #126 among its holdings.

33 funds tracked by Wall St. Rank hold MAIA as of Q1 2026.

  • 683 Capital Management held 1,066,666 shares of MAIA Biotechnology worth $1.49M as of Q1 2026.
  • MAIA Biotechnology was a new 683 Capital Management position in Q1 2026.
  • MAIA Biotechnology made up 0.08% of 683 Capital Management's portfolio in Q1 2026, its #126 holding.
  • 33 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.